Outlook Therapeutics Inc
OTLK2.010USD
+0.080+4.15%
收盤 08/04, 16:00（美東）報價延遲15分鐘
66.14M總市值
3.13本益比TTM
關於 Outlook Therapeutics Inc 公司
Outlook Therapeutics, Inc. 是一家生物製藥公司。該公司專注於開發和商業化 ONS-5010/LYTENAVA (bevacizumab-gamma)，這是一種用於治療視網膜疾病的貝伐單抗眼科製劑。該公司正在推進 ONS-5010/LYTENAVA (bevacizumab-vikg)，這是一種用於治療溼性老年性黃斑變性 (wet AMD)、糖尿病性黃斑水腫 (DME) 和視網膜分支靜脈阻塞 (BRVO) 的貝伐單抗研究性眼科製劑。 Bevacizumab-vikg 是一種重組人源化單克隆抗體 (mAb)，可選擇性地與人類血管內皮生長因子 (VEGF) 的所有同工型高親和力結合，並通過空間阻斷 VEGF 與內皮細胞表面受體 Flt-1 (VEGFR-1) 和 KDR (VEGFR-2) 的結合來中和 VEGF 的生物活性。ONS-5010/LYTENAVA 由三項臨牀試驗組成，分別稱爲 NORSE ONE、NORSE TWO 和 NORSE THREE。
公司簡介
公司代碼OTLK
公司名稱Outlook Therapeutics Inc
上市日期Jun 13, 2016
CEOMr. Robert Charles Jahr
員工數量23
證券類型Ordinary Share
年結日Jun 13
公司地址111 S. Wood Avenue
城市ISELIN
上市交易所NASDAQ Capital Market Consolidated
國家United States of America
郵編08830
電話16096193990
網址https://outlooktherapeutics.com/
公司代碼OTLK
上市日期Jun 13, 2016
CEOMr. Robert Charles Jahr
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Jeff Evanson
Mr. Jeff Evanson
Chief Commercial Officer
Chief Commercial Officer
37.30K
--
Mr. Kurt J. Hilzinger
Mr. Kurt J. Hilzinger
Independent Director
Independent Director
23.66K
--
Mr. Faisal Ghiath Sukhtian
Mr. Faisal Ghiath Sukhtian
Independent Chairman of the Board
Independent Chairman of the Board
3.40K
--
Mr. Yezan Munther Haddadin
Mr. Yezan Munther Haddadin
Independent Director
Independent Director
3.17K
--
Ms. Jenene Thomas
Ms. Jenene Thomas
Investor Relations
Investor Relations
--
--
Mr. Lawrence A. (Larry) Kenyon
Mr. Lawrence A. (Larry) Kenyon
Chief Financial Officer, Executive Vice President, Treasurer, Company Secretary, Director
Chief Financial Officer, Executive Vice President, Treasurer, Company Secretary, Director
--
--
Dr. Julia A. Haller, M.D.
Dr. Julia A. Haller, M.D.
Independent Director
Independent Director
--
--
Mr. Julian S. Gangolli
Mr. Julian S. Gangolli
Independent Director
Independent Director
--
--
Prof. Dr. Gerd Auffarth, M.D.
Prof. Dr. Gerd Auffarth, M.D.
Independent Director
Independent Director
--
--
Mr. Andong Huang
Mr. Andong Huang
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Jeff Evanson
Mr. Jeff Evanson
Chief Commercial Officer
Chief Commercial Officer
37.30K
--
Mr. Kurt J. Hilzinger
Mr. Kurt J. Hilzinger
Independent Director
Independent Director
23.66K
--
Mr. Faisal Ghiath Sukhtian
Mr. Faisal Ghiath Sukhtian
Independent Chairman of the Board
Independent Chairman of the Board
3.40K
--
Mr. Yezan Munther Haddadin
Mr. Yezan Munther Haddadin
Independent Director
Independent Director
3.17K
--
Ms. Jenene Thomas
Ms. Jenene Thomas
Investor Relations
Investor Relations
--
--
Mr. Lawrence A. (Larry) Kenyon
Mr. Lawrence A. (Larry) Kenyon
Chief Financial Officer, Executive Vice President, Treasurer, Company Secretary, Director
Chief Financial Officer, Executive Vice President, Treasurer, Company Secretary, Director
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 5月17日 週六
更新時間: 5月17日 週六
持股股東
股東類型
持股股東
持股股東
佔比
GMS Ventures and Investments
32.12%
Syntone Ventures LLC
4.04%
Schonfeld Strategic Advisors LLC
3.68%
BlackRock Institutional Trust Company, N.A.
2.79%
Sphera Funds Management Ltd.
2.03%
Other
55.34%
持股股東
持股股東
佔比
GMS Ventures and Investments
32.12%
Syntone Ventures LLC
4.04%
Schonfeld Strategic Advisors LLC
3.68%
BlackRock Institutional Trust Company, N.A.
2.79%
Sphera Funds Management Ltd.
2.03%
Other
55.34%
股東類型
持股股東
佔比
Corporation
38.13%
Investment Advisor
7.11%
Hedge Fund
6.73%
Investment Advisor/Hedge Fund
2.50%
Research Firm
0.39%
Bank and Trust
0.19%
Individual Investor
0.18%
Other
44.77%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
199
23.31M
55.24%
+2.45M
2025Q1
206
18.99M
51.79%
+1.54M
2024Q4
199
13.00M
49.47%
-2.41M
2024Q3
196
16.85M
70.81%
+1.73M
2024Q2
189
16.98M
71.93%
+3.50M
2024Q1
185
15.51M
74.39%
+7.93M
2023Q4
178
7.21M
55.91%
-348.31K
2023Q3
180
7.28M
56.56%
-251.17K
2023Q2
176
8.12M
63.26%
-296.08K
2023Q1
174
8.04M
62.65%
-205.25K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
GMS Ventures and Investments
13.55M
32.12%
+4.29M
+46.25%
May 27, 2025
Syntone Ventures LLC
1.71M
4.04%
+714.29K
+72.07%
Apr 17, 2024
Schonfeld Strategic Advisors LLC
1.55M
3.68%
+1.55M
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.18M
2.79%
+149.20K
+14.52%
Mar 31, 2025
Sphera Funds Management Ltd.
857.14K
2.03%
--
--
Apr 10, 2025
The Vanguard Group, Inc.
837.41K
1.98%
-15.13K
-1.78%
Mar 31, 2025
Tenshi Healthcare Pte. Ltd
831.85K
1.97%
-135.72K
-14.03%
Jan 30, 2024
Geode Capital Management, L.L.C.
433.85K
1.03%
+86.62K
+24.95%
Mar 31, 2025
Tang Capital Management, LLC
400.00K
0.95%
+217.50K
+119.18%
Mar 31, 2025
Steward Partners Investment Advisory, LLC
366.20K
0.87%
+366.19K
+2615621.43%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
iShares Micro-Cap ETF
0.01%
iShares Russell 2000 Value ETF
0%
ProShares UltraPro Russell2000
0%
ProShares Hedge Replication ETF
0%
Global X Russell 2000 ETF
0%
iShares Russell 3000 ETF
0%
iShares Russell 2000 ETF
0%
iShares Russell 2000 Growth ETF
0%
Proshares Ultra Russell 2000
0%
Global X Russell 2000 Covered Call ETF
0%
iShares Micro-Cap ETF
佔比0.01%
iShares Russell 2000 Value ETF
佔比0%
ProShares UltraPro Russell2000
佔比0%
ProShares Hedge Replication ETF
佔比0%
Global X Russell 2000 ETF
佔比0%
iShares Russell 3000 ETF
佔比0%
iShares Russell 2000 ETF
佔比0%
iShares Russell 2000 Growth ETF
佔比0%
Proshares Ultra Russell 2000
佔比0%
Global X Russell 2000 Covered Call ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Mar 12, 2024
Merger
20<1
Mar 12, 2024
Merger
20<1
Mar 12, 2024
Merger
20<1
Mar 12, 2024
Merger
20<1
公告日期
類型
比率
Mar 12, 2024
Merger
20<1
Mar 12, 2024
Merger
20<1
Mar 12, 2024
Merger
20<1
Mar 12, 2024
Merger
20<1
